<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407028</url>
  </required_header>
  <id_info>
    <org_study_id>GLR-NIH-2015</org_study_id>
    <nct_id>NCT02407028</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Brain Injury Treatment Trial</brief_title>
  <acronym>HOBIT</acronym>
  <official_title>Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin Healthcare Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hennepin Healthcare Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this innovative adaptive phase II trial design is to determine the optimal&#xD;
      combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate&#xD;
      improvement in the outcome of severe TBI patients in a subsequent phase III trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical and clinical investigations strongly indicate that hyperbaric oxygen (HBO2) is&#xD;
      physiologically active in improving the destructive processes in severe Traumatic Brain&#xD;
      Injury (TBI). However, prior to a definitive efficacy study, important information is&#xD;
      required regarding optimizing the HBO2 treatment paradigm instituted in terms of pressure and&#xD;
      whether NBH enhances the clinical effectiveness of the HBO2 treatment. Preclinical&#xD;
      investigators working with TBI models have used pressures varying from 1.5 to 3.0 atmospheres&#xD;
      absolute (ATA). Clinical investigators have used pressure varying from 1.5 to 2.5 ATA.&#xD;
      However, the lungs in severe TBI patients have frequently been compromised by direct lung&#xD;
      injury and/or acquired ventilator pneumonia and are susceptible to oxygen (O2) toxicity.&#xD;
      Working within these constraints, it is essential to determine the most effective HBO2&#xD;
      treatment parameters without producing O2 toxicity and clinical complications. This proposed&#xD;
      clinical trial is designed to answer these questions and to provide important data to plan a&#xD;
      definitive efficacy trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOS-E)</measure>
    <time_frame>Assessment at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ICP elevation</measure>
    <time_frame>First 5 days</time_frame>
    <description>The duration of ICP elevation will be measured using the area under the curve methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic intensity level scores for controlling intracranial pressure (ICP)</measure>
    <time_frame>First 5 days</time_frame>
    <description>This tracks the level of therapies used to control ICP during the first 5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain tissue partial pressure of oxygen</measure>
    <time_frame>First 5 days</time_frame>
    <description>This outcome will be measured only in patients with LICOX monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>180 days</time_frame>
    <description>Events resulting in death, a life-threatening adverse event, or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak brain tissue oxygen (P02) during HBO treatments</measure>
    <time_frame>First 5 days</time_frame>
    <description>To examine the association between peak brain tissue PO2 during hyperbaric treatment and favorable outcome at 6-months (measured by the GOS-E).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA, no NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA, no NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA, no NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA + NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA + NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA + NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normobaric Hyperoxia (NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care for severe TBI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (1.5 ATA, no NBH)</intervention_name>
    <description>HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA, no NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.0 ATA, no NBH)</intervention_name>
    <description>HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA, no NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.5 ATA, no NBH)</intervention_name>
    <description>HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA, no NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (1.5 ATA + NBH)</intervention_name>
    <description>HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA + NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.0 ATA + NBH)</intervention_name>
    <description>HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA + NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.5 ATA + NBH)</intervention_name>
    <description>HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA + NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normobaric Hyperoxia (NBH)</intervention_name>
    <description>100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead</description>
    <arm_group_label>Normobaric Hyperoxia (NBH)</arm_group_label>
    <other_name>NBH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Will be treated with usual and customary care for severe traumatic brain injury</description>
    <arm_group_label>Usual care</arm_group_label>
    <other_name>Standard of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 16 years or older and 65 years or younger&#xD;
&#xD;
          -  Present with severe TBI, defined as Glasgow Coma Scale (GCS) of 3 to 8.&#xD;
&#xD;
          -  Marshall computerized tomography (CT) score &gt;1 in patients with a GCS of 7 or 8 or&#xD;
             patients with an alcohol level &gt;200 mg/dl&#xD;
&#xD;
          -  Ability to initiate the first hyperbaric oxygen treatment within 8 hours of admission&#xD;
             in patients not requiring a craniotomy/craniectomy or any other major surgical&#xD;
             procedure OR&#xD;
&#xD;
          -  Ability to initiate the first hyperbaric oxygen treatment within 14 hours of admission&#xD;
             in patients requiring a craniotomy/craniectomy or major surgical procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  First hyperbaric oxygen treatment cannot be initiated within 24 hours of injury&#xD;
&#xD;
          -  GCS of 3 with mid-position and non-reactive pupils bilaterally (4mm)&#xD;
&#xD;
          -  Penetrating head injury&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Pre-existing neurologic disease (e.g. TBI or stroke or neurodegenerative disorder)&#xD;
             with confounding residual neurologic deficits&#xD;
&#xD;
          -  Unstable acute spinal cord injury&#xD;
&#xD;
          -  Fixed coagulopathy&#xD;
&#xD;
          -  Severe hypoxia&#xD;
&#xD;
          -  Cardiopulmonary resuscitation performed&#xD;
&#xD;
          -  Coma suspected to de due to primarily non-TBI causes&#xD;
&#xD;
          -  Any contraindications to the study intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaylan L Rockswold, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Barsan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byron Gajewski, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick K Korley, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaylan L. Rockswold, M.D., Ph.D.</last_name>
    <phone>612-873-2810</phone>
    <email>gaylan.rockswold@hcmed.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSD Medical Center - Hillcrest Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Curry</last_name>
      <email>tcurry@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Constantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy RODRIGUEZ</last_name>
      <email>Tracy.Rodriguez@tenethealth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Borrego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Fairfield</last_name>
      <email>catherine-fairfield@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Mohr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronda A Ronda PETREY</last_name>
      <email>ronda.petrey@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Hatton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Sult</last_name>
      <email>lsult@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Kinjal Sethuraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhan Ayaz</last_name>
      <email>sfayaz@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Lagina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloe LAWYER</last_name>
      <email>lawye010@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Bergman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooklin K Zimmerman</last_name>
      <email>brooklin.zimmerman@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmalee Metzler</last_name>
      <email>emmalee.metzler@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Herren</last_name>
      <email>luke.herren@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Heath Services</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise J Louise LACHOWSKY</last_name>
      <email>lachows@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Kesh Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gajewski BJ, Meinzer C, Berry SM, Rockswold GL, Barsan WG, Korley FK, Martin RH. Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials. Stat Med. 2019 Jul 30;38(17):3123-3138. doi: 10.1002/sim.8167. Epub 2019 May 9.</citation>
    <PMID>31070807</PMID>
  </reference>
  <reference>
    <citation>Gajewski BJ, Berry SM, Barsan WG, Silbergleit R, Meurer WJ, Martin R, Rockswold GL. Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling. Pharm Stat. 2016 Sep;15(5):396-404. doi: 10.1002/pst.1755. Epub 2016 Jun 15.</citation>
    <PMID>27306921</PMID>
  </reference>
  <reference>
    <citation>Rockswold SB, Rockswold GL, Zaun DA, Zhang X, Cerra CE, Bergman TA, Liu J. A prospective, randomized clinical trial to compare the effect of hyperbaric to normobaric hyperoxia on cerebral metabolism, intracranial pressure, and oxygen toxicity in severe traumatic brain injury. J Neurosurg. 2010 May;112(5):1080-94. doi: 10.3171/2009.7.JNS09363.</citation>
    <PMID>19852540</PMID>
  </reference>
  <reference>
    <citation>Rockswold SB, Rockswold GL, Zaun DA, Liu J. A prospective, randomized Phase II clinical trial to evaluate the effect of combined hyperbaric and normobaric hyperoxia on cerebral metabolism, intracranial pressure, oxygen toxicity, and clinical outcome in severe traumatic brain injury. J Neurosurg. 2013 Jun;118(6):1317-28. doi: 10.3171/2013.2.JNS121468. Epub 2013 Mar 19.</citation>
    <PMID>23510092</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

